APC-labeled streptavidin, for use in LANCE® TR-FRET protein binding assays.
true falseFor research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
PerkinElmer offers two versions of SureLight APC-SA: one for protein binding assays, and one for kinase assays. SureLight APC-SA for protein binding assays has a ratio of APC:streptavidin that has been optimized to achieve the best performance in protein binding applications.
LANCE® (Lanthanide chelate excite) and LANCE® Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One molecule of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore [ULight™ dye, allophycocyanin (APC), etc.]. Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm (for ULight dye and APC).
| Antibody Conjugates | Streptavidin |
|---|---|
| Automation Compatible | Yes |
| Detection Method | Time-Resolved Fluorescence (TRF), TR-FRET |
| Experimental Type | In vitro |
| Fluorophore | SureLight APC |
| Product Brand Name | LANCE SureLight |
| Shipping Condition | Blue Ice |
| Unit Size | 1 mg |
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.
